Meeting
2022 ASCO Annual Meeting
A multicenter, open-label, phase 1a/b study of HC-7366, a modulator of integrated stress response (ISR) kinase GCN2 in subjects with advanced solid tumors.
Authors
Meredith Pelster
The University of Texas MD Anderson Cancer Center, Houston, TX
Meredith Pelster , Marcio Torre , Geoffrey Sumithran Kannan , Michele Anne Gargano , Paulette Mattson , Blaine Rathmann , Nandita Bose , Jose Luis Iglesias
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT05121948
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3179)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3179
Abstract #
TPS3179
Poster Bd #
156b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).
First Author: Jacob M. Sands
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam
Poster
2023 ASCO Annual Meeting
A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.
First Author: Xiaojie Hu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2-positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial.
First Author: Dan Liu